116 related articles for article (PubMed ID: 38211405)
1. Prognosis and conditional survival among women with newly diagnosed ovarian cancer.
Szamreta EA; Monberg MJ; Desai KD; Li Y; Othus M
Gynecol Oncol; 2024 Jan; 180():170-177. PubMed ID: 38211405
[TBL] [Abstract][Full Text] [Related]
2. Comparison of advanced ovarian cancer patients treated with or without bevacizumab in the US Community Oncology Clinics.
DeClue RW; Szamreta EA; Gautam S; Fisher MD; Monberg MJ
Future Oncol; 2023 May; 19(16):1113-1124. PubMed ID: 37170823
[TBL] [Abstract][Full Text] [Related]
3. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data.
Pérol M; Felip E; Dafni U; Polito L; Pal N; Tsourti Z; Ton TGN; Merritt D; Morris S; Stahel R; Peters S
Ann Oncol; 2022 May; 33(5):511-521. PubMed ID: 35218887
[TBL] [Abstract][Full Text] [Related]
5. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
6. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.
Velcheti V; Hu X; Yang L; Pietanza MC; Burke T
Front Oncol; 2022; 12():834761. PubMed ID: 35402266
[TBL] [Abstract][Full Text] [Related]
8. Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma.
Gounder MM; Merriam P; Ratan R; Patel SR; Chugh R; Villalobos VM; Thornton M; Van Tine BA; Abdelhamid AH; Whalen J; Yang J; Rajarethinam A; Duh MS; Bobbili PJ; Huynh L; Totev TI; Lax AK; Agarwal S; Demetri GD
Cancer; 2021 Apr; 127(8):1311-1317. PubMed ID: 33296083
[TBL] [Abstract][Full Text] [Related]
9. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J
J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776
[TBL] [Abstract][Full Text] [Related]
10. Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer.
Jahanzeb M; Lin HM; Pan X; Yin Y; Wu Y; Nordstrom B; Socinski MA
Oncologist; 2020 Oct; 25(10):867-877. PubMed ID: 32490560
[TBL] [Abstract][Full Text] [Related]
11. Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study.
Girard N; Bar J; Garrido P; Garassino MC; McDonald F; Mornex F; Filippi AR; Smit HJM; Peters S; Field JK; Christoph DC; Sibille A; Fietkau R; Haakensen VD; Chouaid C; Markman B; Hiltermann TJN; Taus A; Sawyer W; Allen A; Chander P; Licour M; Solomon B
J Thorac Oncol; 2023 Feb; 18(2):181-193. PubMed ID: 36307040
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab Utilization and Clinical Outcomes Among Patients With Advanced Melanoma in the US Community Oncology Setting: An Updated Analysis.
Cowey CL; Scherrer E; Boyd M; Aguilar KM; Beeks A; Krepler C
J Immunother; 2021 Jul-Aug 01; 44(6):224-233. PubMed ID: 33734142
[TBL] [Abstract][Full Text] [Related]
14. Conditional survival nomogram predicting real-time prognosis of locally advanced breast cancer: Analysis of population-based cohort with external validation.
Meng X; Hao F; Ju Z; Chang X; Guo Y
Front Public Health; 2022; 10():953992. PubMed ID: 36388300
[TBL] [Abstract][Full Text] [Related]
15. Development of a Prognostic Factor Index Among Women With HR
Vidal GA; Carter GC; Gilligan AM; Saverno K; Zhu YE; Price GL; DeLuca A; Smyth EN; Rybowski S; Huang YJ; Schwartzberg LS
Clin Breast Cancer; 2021 Aug; 21(4):317-328.e7. PubMed ID: 33678566
[TBL] [Abstract][Full Text] [Related]
16. Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries.
Mogal HD; Levine EA; Russell G; Shen P; Stewart JH; Votanopoulos KI
Ann Surg Oncol; 2016 Feb; 23(2):534-8. PubMed ID: 26289808
[TBL] [Abstract][Full Text] [Related]
17. Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.
Sayer MR; Mambetsariev I; Lu KH; Wong CW; Duche A; Beuttler R; Fricke J; Pharoan R; Arvanitis L; Eftekhari Z; Amini A; Koczywas M; Massarelli E; Roosan MR; Salgia R
Front Oncol; 2023; 13():1064169. PubMed ID: 36860308
[TBL] [Abstract][Full Text] [Related]
18. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
Banerjee S; Moore KN; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Oza A; González-Martín A; Aghajanian C; Bradley WH; Holmes E; Lowe ES; DiSilvestro P
Lancet Oncol; 2021 Dec; 22(12):1721-1731. PubMed ID: 34715071
[TBL] [Abstract][Full Text] [Related]
19. Conditional survival after radical nephroureterectomy for upper tract carcinoma.
Ploussard G; Xylinas E; Lotan Y; Novara G; Margulis V; Rouprêt M; Matsumoto K; Karakiewicz PI; Montorsi F; Remzi M; Seitz C; Scherr DS; Kapoor A; Fairey AS; Rendon R; Izawa J; Black PC; Lacombe L; Shariat SF; Kassouf W
Eur Urol; 2015 Apr; 67(4):803-12. PubMed ID: 25145551
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis.
Brufsky A; Liu X; Li B; McRoy L; Layman RM
Front Oncol; 2022; 12():865292. PubMed ID: 35860587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]